Literature DB >> 2854957

Antiviral activities of 2'-deoxyribofuranosyl and arabinofuranosyl analogs of sangivamycin against retro- and DNA viruses.

D F Smee1, P A McKernan, H A Alaghamandan, K B Frank, K Ramasamy, G R Revankar, R K Robins.   

Abstract

Eight sugar-modified pyrrolopyrimidine nucleoside analogs related to the antibiotic sangivamycin were evaluated in cell culture against herpes simplex types 1 (HSV-1) and 2 (HSV-2), cytomegalovirus (CMV), adenovirus, and visna virus. Five of the compounds were highly active against most of the viruses with 50% inhibition (ED50) values of 1-10 microM. The selectivity of the agents was low, with inhibition of uninfected cell proliferation occurring within 5-fold that of the virus ED50 for most of the viruses. The compounds did not possess RNA virus-inhibitory activity when evaluated against certain myxo-, paramyxo-, picorna-, reo-, rhabdo-, and togaviruses. Two of the nucleosides were tested further in a cell line persistently infected with Friend leukemia virus where they were inhibitory to both virus yield and cell proliferation at 4-5 microM. Several of the sangivamycin analogs were tested in animal models using a twice-a-day treatment regimen. They proved to be inactive against HSV-1, murine CMV and/or Friend leukemia virus infections in mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2854957     DOI: 10.1016/0166-3542(88)90045-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  2 in total

1.  Evaluation of continuous cell lines in antiviral studies with murine cytomegalovirus.

Authors:  D F Smee; A Colletti; H A Alaghamandan; L B Allen
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 2.  Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides.

Authors:  Pavla Perlíková; Michal Hocek
Journal:  Med Res Rev       Date:  2017-08-23       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.